cagrisema semaglutide cagrilintide phase 3 results 2024 2025 obesity Presenters to provide first look at data from REIMAGINE trials of cagrilintide/semaglutide for type 2 diabetes management Cagrilintide–Semaglutide in Adults with Overweight
Description
As with any peptide therapy, it is recommended to consult a qualified practitioner before use
Clinical signs are indistinct and include lethargy, depression, ataxia, anorexia and intermittent vomiting, and in severe cases, can induce neurological disease and blindness in cats
That includes one of the most important: the immune system
What are the common side effects
01751-7/asset/f8ffb968-301f-4b4c-9c56-cfb01106603a/main.assets/gr2a_lrg.jpg)
PMID 34942066
Not intended for clinical, diagnostic, or therapeutic applications
